For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
First-Line Chemotherapy Plus Pembrolizumab and Olaparib for BRCA Non-Mutated Advanced Epithelial Ovarian Cancer (EOC)
To test the safety of the study drug, pembrolizumab (MK- 3475) with chemotherapy followed by olaparib OR pembrolizumab with chemotherapy compared to chemotherapy alone to see how well the drugs work and to see how your body handles them.
DiagnosisUntreated Non-Mutated BRCA Advanced Epithelial Ovarian Cancer (EOC), fallopian tube cancer or primary peritoneal cancer.
First line, BRCA non-muted, treatment naïve, Stage III or IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1 - Carboplatin/paclitaxel for 5 cycles plus pembrolizumab 200 mg every 3 weeks for up to 35 infusions and olaparib 300 mg (twice daily).
- Group 2 - Carboplatin/paclitaxel for 5 cycles plus pembrolizumab 200 mg every 3 weeks for up to 35 infusions and olaparib placebo.
- Group 3 - Carboplatin/paclitaxel for 5 cycles plus pembrolizumab placebo every 3 weeks for up to 35 infusions and olaparib placebo.
For more information, visit ClinicalTrials.gov